Articles by David Egilman Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan:

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

Purdue’s strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and consumers through an apparently independent entity called “Partners Against Pain,” but ultimately controlled by the company itself. 

Read more

Purdue Circumvented the Regulator to Promote OxyContin, Hiding Its Real Risk of Addiction

In 2001, the Food and Drug Administration required Purdue to change OxyContin’s patient package inserts to make addiction risks more evident. The company altered the label to make it appear as though illegal use and abuse were the only addiction-related problems associated with OxyContin. Eventually, Purdue hired the FDA’s medical reviewer for OxyContin. 

Read more

OxyContin’s Academic Marketing: The Studies That Fueled the Opioid Crisis

Purdue Pharmaceuticals used to cite three major studies to argue that in prescribing OxyContin, addiction-risk was not significant. The most influential of those studies did not even mention OxyContin, because it was completed twenty-five years before OxyContin was sold. After more than a decade, the company had to admit that “data are not available to establish the true incidence of addiction.”

Read more